



Journal of Innovations in Applied Pharmaceutical Science [JIAPS]

Content available at: www.saap.org.in ISSN: 2455-5177



RP-HPLC IN MODERN PHARMACEUTICAL ANALYSIS: FROM FUNDAMENTAL PRINCIPLES TO METHOD VALIDATION AND EMERGING TRENDS

Thirunahari Prathima¹, Kamarapu Sudheer Kumar¹, Kothapally Daniel², Mounika Konatham³, Boggula Narender^{3*}

¹Sri Kakatiya Institute of Pharmaceutical Sciences, Unikicherla, Hanamkonda, Warangal - 506370, Telangana, India.

²S.V.S. Group of Institutions, Bheemaram, Hanamkonda, Warangal - 506015, Telangana, India.

³Omega College of Pharmacy, Edulabad, Ghatkesar, Hyderabad - 501301, Telangana, India.

Article History	Abstract
Received: 22-10-2025 Revised: 03-11-2025 Accepted: 14-12-2025	Reversed-phase high-performance liquid chromatography (RP-HPLC) is one of the most widely used analytical techniques for the separation, identification, and quantification of pharmaceutical compounds. In RP-HPLC, a non-polar stationary phase, commonly C18-bonded silica, is used with a relatively polar mobile phase, generally consisting of water or buffer and an organic modifier such as methanol or acetonitrile. Separation primarily depends on the hydrophobic interactions between analytes and the stationary phase, while factors such as pH, ionic strength, organic-solvent composition, flow rate, and column temperature influence retention and selectivity. RP-HPLC offers high resolution, sensitivity, reproducibility, and versatility and is therefore extensively employed in pharmaceutical quality control, assay determination, impurity profiling, dissolution testing, stability studies, and biological sample analysis. Method validation is an essential component of pharmaceutical RP-HPLC and includes characteristics such as specificity, accuracy, precision, linearity, range, detection limit, and quantitation limit according to the intended analytical purpose. Despite its advantages, RP-HPLC has limitations including high solvent consumption, relatively expensive instrumentation, column deterioration, and the generation of chemical waste. Recent developments involving analytical quality by design (AQbD), shorter columns, greener solvents, and improved detection systems are contributing to more efficient and sustainable RP-HPLC methods. This review briefly discusses the principles, advantages, disadvantages, applications, and future significance of RP-HPLC in pharmaceutical analysis.
Keywords: <i>RP-HPLC, reversed-phase chromatography, pharmaceutical analysis, C₁₈ column, method validation, quality control.</i>	

This article is licensed under a Creative Commons Attribution-Non Commercial 4.0 International License.

Copyright © 2025 Author[s] retain the copyright of this article.



*Corresponding Author

Boggula Narender

Production and Hosted by

www.saap.org.in

Introduction

High-performance liquid chromatography (HPLC) is a powerful instrumental analytical technique used for separating, identifying, and quantifying components present in complex mixtures. Among the different modes of HPLC, reversed-phase HPLC is the most commonly employed because of its broad applicability to pharmaceutical compounds with diverse physicochemical properties. In RP-HPLC, the stationary phase is non-polar or hydrophobic, whereas the mobile phase is comparatively polar. C18 (octadecylsilane)-bonded silica is one of the most frequently used stationary phases [1-5].

The retention mechanism in RP-HPLC involves partitioning and adsorption of analytes between the mobile and stationary phases. Hydrophobicity, logP, pKa, mobile-phase pH, organic modifier, buffer concentration, and other interactions can substantially influence analyte retention and selectivity [1]. Consequently, appropriate selection and optimization of

chromatographic conditions are essential for achieving satisfactory resolution and reproducibility.

RP-HPLC has become an important tool throughout pharmaceutical development, from drug discovery and formulation development to routine quality control and stability testing. It is particularly useful for determining drug content, degradation products, process-related impurities, and dissolution profiles [2,3]. Current analytical practice also emphasizes scientifically based method development and validation. ICH Q2(R2) provides a framework for demonstrating that an analytical procedure is suitable for its intended purpose, while ICH Q14 provides principles for analytical procedure development [4,6].

Principle

In RP-HPLC, the stationary phase is hydrophobic while the mobile phase is relatively polar. A sample injected into the chromatographic system is carried through the column by the mobile phase. Components having greater hydrophobic interaction with the stationary phase are retained longer, whereas more polar compounds generally elute earlier and shown in figure 1 [7].




Figure 01: Schematic representation of RP-HPLC instrumentation

The separation can be influenced by:

- **Stationary phase:** C18, C8, phenyl and other bonded phases.
- **Mobile phase:** Water/buffer combined with methanol or acetonitrile.
- **pH:** Particularly important for ionizable pharmaceutical compounds.
- **Organic modifier:** Changes analyte retention and selectivity.
- **Flow rate:** Influences analysis time and chromatographic efficiency.
- **Column temperature:** Can affect retention and selectivity.
- **Detection wavelength:** Important for UV/visible detection and sensitivity.

Method development therefore involves systematic optimization of these parameters to obtain adequate resolution, acceptable peak shape, suitable retention time, and reliable quantitative performance [8-10].

Advantages

i. High separation efficiency

RP-HPLC provides excellent resolution of structurally related compounds, pharmaceutical ingredients, impurities, and degradation products. This makes it particularly useful for complex pharmaceutical samples [11-12]. RP-HPLC has advantages and shown in Figure 02 [13].

ii. High sensitivity

With suitable detectors, particularly UV/visible, fluorescence, or mass spectrometric detection, RP-HPLC can detect and quantify compounds at low concentrations.




Figure 02: Advantages of RP-HPLC

iii. Good accuracy and reproducibility

When properly developed and validated, RP-HPLC methods can provide accurate, precise, and reproducible results, making them suitable for routine quality-control applications [14].

analyst-to-analyst variability.

iv. Broad applicability

RP-HPLC can be applied to a wide range of pharmaceutical substances, including many non-polar, moderately polar, and ionizable compounds. C18 columns are particularly versatile and remain widely used for pharmaceutical API quantification [13].

v. Quantitative capability

The technique allows reliable quantitative estimation of active pharmaceutical ingredients, impurities, degradation products, and metabolites.

vi. Suitable for stability-indicating methods

RP-HPLC can separate the parent drug from degradation products and is therefore widely used in stability studies and stability-indicating assay procedures.

vii. Automation

Modern HPLC systems allow automated injection, data acquisition, peak integration, system suitability assessment, and report generation, reducing

Limitations

RP-HPLC has limitations and shown in Figure 03 [14].




Figure 03: Limitations of RP-HPLC

a. High initial cost

HPLC instruments, columns, detectors, pumps, and associated accessories are relatively expensive compared with simpler analytical techniques.

b. High solvent consumption

Conventional HPLC methods may require considerable quantities of methanol, acetonitrile, and aqueous buffers. This increases operating costs and chemical waste generation [13].

c. Column deterioration

Chromatographic columns have a finite lifetime. Extreme pH, contaminated samples, inappropriate solvents, and improper storage can reduce column performance.

d. Time-consuming method development

Optimization of mobile-phase composition, pH, column chemistry, flow rate, temperature, and detection conditions may require considerable experimental work.

e. Generation of chemical waste

The disposal of organic solvents and buffer-containing mobile phase's presents environmental and safety concerns.

Consequently, greener chromatographic approaches are increasingly being explored [14].

f. Limited suitability for some compounds

Highly polar compounds may show poor retention under conventional RP-HPLC conditions, while compounds lacking suitable chromophores may require alternative detectors or derivatization.

Applications

RP-HPLC has extensive applications in pharmaceutical research, development, and manufacturing, quality control etc. and shown in figure 4 [15].




Figure 04: Applications of RP-HPLC

A. Assay of pharmaceutical formulations

RP-HPLC is widely used for determining the concentration of APIs in tablets, capsules, injections, oral liquids, creams, and other dosage forms [16-18].

B. Impurity profiling

The technique can separate and quantify process-related impurities, related substances, and degradation products. This is particularly important for demonstrating pharmaceutical product quality.

C. Stability studies

RP-HPLC is frequently employed to monitor drug degradation under stress conditions such as acidic, alkaline, oxidative, thermal, and photolytic conditions. The ability to separate the drug from its degradation products makes it valuable for stability-indicating analytical procedures [19].

D. Dissolution testing

Samples collected during dissolution studies can be analysed by RP-HPLC to determine the amount of drug released from pharmaceutical dosage forms.

E. Bio-analytical applications

With appropriate sample preparation and sensitive detection, RP-HPLC can be used for estimation of drugs and metabolites in biological matrices such as plasma and urine.

F. Pharmaceutical method development

RP-HPLC is routinely used during formulation development to determine drug content, evaluate compatibility, monitor degradation, and optimize pharmaceutical formulations.

G. Quality control

Validated RP-HPLC procedures are widely used for release testing and routine quality control of drug substances and products. ICH Q2 (R2) specifically recognizes analytical procedures used for purposes including assay/potency, purity, impurities, identity, and other quantitative or qualitative measurements [20].

H. Research and advanced analytical applications

RP-HPLC can be coupled with advanced detectors, including mass spectrometry, to improve identification and

quantification of analytes. Current method-development approaches increasingly incorporate AQbD and risk-based principles to improve robustness and reproducibility [21-30].

Method Validation

Validation is essential before using an RP-HPLC procedure for regulated pharmaceutical analysis. According to ICH Q2 (R2), the validation characteristics selected should be appropriate for the intended purpose of the analytical procedure [31-37].




Figure 05: Method Validation of RP-HPLC

Important characteristics may include:

- **Specificity/selectivity**
- **Accuracy**
- **Precision**
- **Linearity**
- **Range**
- **Detection limit (DL)**
- **Quantitation limit (QL)**
- **Robustness**
- **System suitability**, where applicable

The current ICH Q2 (R2) guideline is applicable to analytical procedures used for release and stability testing of commercial drug substances and products and provides recommendations for demonstrating fitness for purpose. ICH Q14 complements Q2(R2) by describing science- and risk-based approaches for analytical procedure development and shown in figure 5 [36].

Recent Trends

Modern RP-HPLC development is moving toward faster, more robust, automated, and environmentally sustainable methods. Shorter columns, reduced flow rates, optimized solvent consumption, alternative stationary phases, and greener mobile phases can decrease analysis time and waste generation. AQbD approaches use risk assessment and design of experiments to understand critical method parameters and improve robustness [37-47].

The increasing use of computational tools, automated method optimization, UHPLC-compatible columns, and LC-MS coupling is further extending the analytical capabilities of reversed-phase chromatography. These developments are particularly important for complex pharmaceutical products and low-level impurity analysis [48-50].

CONCLUSION

RP-HPLC remains one of the most important analytical techniques in pharmaceutical science because of its high separation efficiency, sensitivity, reproducibility, and versatility. Its extensive applications include assay

determination, impurity profiling, stability studies, dissolution testing, bio-analysis, and routine quality control. C18-based RP-HPLC methods are particularly popular because of their broad applicability to pharmaceutical compounds. Nevertheless, high instrument and solvent costs, column maintenance requirements, and chemical waste generation remain important limitations. The incorporation of ICH Q2(R2)-based validation, ICH Q14 principles, AQbD, shorter chromatographic methods, and greener analytical practices can improve the reliability, efficiency, and sustainability of RP-HPLC. Thus, RP-HPLC is expected to remain a fundamental analytical platform in pharmaceutical research and quality assurance while continuing to evolve toward faster, greener, and more scientifically controlled methodologies.

CONFLICTS OF INTEREST

Nil

REFERENCES

1. Sindhu M, Farana M, Bhavani M, Dandamudi SP, Priya DS, Bakshi V. Stability Indicating RP-HPLC Method for Simultaneous Estimation of Nirmatrelvir and Ritonavir in Bulk and Tablets. *Research Journal of Pharmacy and Technology*. 2025;18(2):594-8.
2. Vekateswarlu K, Venisetty RK, Yellu NR, Keshetty S, Pail MG. Development of HPTLC-UV absorption Densitometry and Sertraline in combination and its application in evaluation of marketed preparation. *Journal of Chromatographic Science*. 2007; 45(8):537-539.
3. Basha A, Sireesha D, Anil D, Talla R, Haque MA, Harshini S. Method development and validation for simultaneous estimation of tenofovir disoproxil fumarate and emtricitabine in pharmaceutical dosage form by RP-HPLC method. *Int J Innovative Pharm Sci Res*. 2015;3:1537-45.
4. Mamatha K, Prasad VV, Haque MA, Bakshi V. Development and validation of RP-HPLC method for simultaneous estimation of levosulpiride and pantoprazole in combined pharmaceutical dosage form. *International Journal of Pharmaceutical Research and Health Sciences*. 2014;2(6):514-8.
5. Kamarapu SK, Vijayanathi BZ, Venisetty RK. Development of RP-HPLC method for the analysis of levocetirizine, 2HCl and ambroxol. HCl in Combination and its Application. *International Journal of Pharmaceutical Sciences and Nanotechnology*. 2010;3:893-6.
6. Dubbaka A, Sireesha D, Bakshi V. Analytical method development and validation for the simultaneous estimation of lamivudine and tenofovir disoproxil fumarate by RP-HPLC method. *MOJ proteomics bioinform*. 2016;4(5):306-9.
7. LaCourse WR, LaCourse ME. General instrumentation in HPLC. In *Liquid Chromatography 2023 Jan 1* (pp. 61-73). Elsevier.
8. Meghana M, Thota S, Venisetty RK. Development and validation of stability-indicating RP-HPLC method for the estimation of Agomelatine in API. *Research Journal of Pharmaceutical, Biological and Chemical Sciences*. 2014;5(1):621-8.
9. Srawanthi P, Dodda S, Battineni JK. Development and validation of RP-HPLC method for simultaneous estimation of sofosbuvir and velpatasvir in bulk and tablet dosage form. *Journal of Advanced Scientific Research*. 2022;13(01):281-5.
10. Shirisha S, Haque MA, Sireesha D, Bakshi V, Harshini S. Development and validation of RP-HPLC method for simultaneous estimation of metformin and linagliptin in combined pharmaceutical dosage form. *Int J Pharm Res Sci*. 2014;2:491-5.
11. Talla R, Haque MA, Veena K, Sireesha D, Harshini S, Vasudha B. Development and Validation for the Simultaneous Estimation of Pioglitazone Hydrochloride and Glimipride in Mixed Dosage Form by RP-HPLC Method. *Asian Journal of Research in Chemistry*. 2015;8(12):711.
12. Srinidhi M, Basha MM, Kumar VR, Kumar JR. Stability indicating RP-HPLC method development and validation for the estimation of sumatriptan in bulk and pharmaceutical dosage form. *Journal of Applied Pharmaceutical Science*. 2016;6(6):020-5.
13. Vyas AJ, Parmar DU, Patel AB, Patel AI, Dudhrejiya AV, Shah SR. Strategic approach for HPLC method development and validation: review. *Asian J Res Pharm Sci*. 2024;14(1):71-76.
14. Nunsavathu SN, Thangabalan B. A RP-HPLC approach to bioanalytical method development and validation: a review. *Asian J Pharm Anal*. 2024;14(1):47-50.
15. Begum SK, Kumari KU, Sajana S. A short review of high-performance liquid chromatography. *Math Stat Eng Appl*. 2022;71(2):410-414
16. Smitha G, Reddy SS, Rasagna M, Priyanka R, Bakshi V, Jukanti R. Bazedoxifene acetate quantification in rat serum with the aid of RP-HPLC: Method development and validation. *World Journal of Pharmaceutical Sciences*. 2015;2357-63.
17. Rupa Y, Makiful P, Haque R, Sireesha D, Vasudha B, Harshini S. Method development and validation for the simultaneous estimation of doxycycline and ornidazole in bulk and pharmaceutical dosage form by using the RP-HPLC method. *Int J Med Nanotechnol: Medtechnano*. 2014;1:179-85.
18. Keshetty S, Venisetty RK, Molmoori V, Ciddi V. Determination of valdecoxib in serum using a HPLC-diode array detector and its application in a pharmacokinetic study. *Die Pharmazie-An International Journal of Pharmaceutical Sciences*. 2006;61(3):245-6.
19. Bhargavi D, Rao BB, Kiran G, Gouthami T, Bakshi V. Method development and validation for related impurities of efavirenz by RP-HPLC method. *Analytical Chemistry Letters*. 2017;7(5):737-47.
20. Priyanka D, Sireesha M, Akiful Haque S, Harshini VB. Method development and validation of Fexofenadine hydrochloride and Montelukast sodium in a combined dosage form by RP-HPLC method. *Int J Med Nanotechnology*. 2014;1:174-8.
21. Aleti P, Venisetty RK, Kamarapu SK. Development of RP-HPLC Method for the Analysis of Imatinib Mesylate Using PDA Detector and Its Application in the Evaluation of

- Marketed Preparation. *International Journal of Pharmacy and Biological Sciences*. 2011;1(2):14-8.
22. Kuchukuntla M, Kaveti VS, Mandhadi JR, Priya DK, Boggula N, Kaveti M. RP-HPLC method for quantification of acridinium and formoterol in bulk and pharmaceutical dosage forms. *Biochemical& Cellular Archives*. 2025;25(1):467.
23. Sravani T, Thota S, Venisetty R, Venumadhav N. RP-HPLC analysis of acebrophylline in API and capsule dosage form. *Res J Pharm*. 2014;5:480-6.
24. Suchitra D, Kumar KS, Bhargavi CS, Spandana R, Krishna PR, Boggula N. Determination of darunavir and cobicistat simultaneously using RP-HPLC in bulk and dosage form. *Biochemical&Cellular Archives*. 2024;24(2):2381.
25. Sravani T, Dandu AM, Sireesha D, Haque AM, Rao P, Bakshi V. Development and Validation of Analytical Method for the Simultaneous Estimation of Telmisartan and Atorvastatin in Pharmaceutical Formulations by RP-HPLC. *Int. J. Innovations. Pharm. Sci. Res*. 2014;2:2980-7.
26. Pokkula S, Thota S, Kumar VR, Nagabandi VK. Development and validation of RP-HPLC method for the determination of methylphenidate hydrochloride in API. *International Journal of PharmTech Research*. 2014;6:462-7.
27. Kumar KS, Suchitra D, Kasu PK, Mandala S, Bhargavi CS, Boggula N. RP-HPLC method for simultaneous estimation of trifluridine and tipiracil in pure and tablet dosage form. *Biochemical& Cellular Archives*. 2024;24(2):2519.
28. Nagula S, Thota S, Kumar VR. Development and validation of a stability indicating RP-HPLC method for the determination of trimetazidine dihydrochloride. *Der Pharma Chemica*. 2014;6(1):149-54.
29. Sowmya Y, Aleti P, Venisetty R. Development and validation of RP-HPLC method for the simultaneous estimation of dutasteride and tamsulosin in tablet dosage form. *International Journal of Pharmacy and Biological Sciences*. 2013;3(4):301-16.
30. Bhadru B, Rao V, Boggula N. Simultaneous estimation of Levodopa and Benserazide by using reverse phase High Performance Liquid Chromatography in API and marketed formulation. *International Journal of Recent Advances in Multidisciplinary Research*. 2023;10(10):9020-4.
31. Ramu K, Aleti P, Venisetty RK. Analytical Method Development and Validation of Simultaneous Estimation of Ezetamibe and Rosuvastatin in Tablet Dosage Form By RP-HPLC. *Res. Art. Pharm. Sci*. 2013;3(4):343-53.
32. Shirisha S, Haque MA, Sireesha D, Bakshi V, Harshini S. Development and validation of RP-HPLC method for simultaneous estimation of metformin and linagliptin in combined pharmaceutical dosage form. *Int J Pharm Res Sci*. 2014;2:491-5.
33. Venisetty RK, Kamarapu SK. RP-HPLC Method development and validation for simultaneous estimation of clidinium bromide, chlordiazepoxide and dicyclomine hydrochloride in bulk and combined tablet dosage forms. *Int J Ad Biomed Pharm Res*. 2013;2(1):35-40.
34. Bojaraju V, Sireesha D, Nasare M, Prasad VV, Diwan PV. Reverse phase high performance liquid chromatographic method for the simultaneous estimation of amoxicillin trihydrate and tinidazole in the tablet dosage form. *Asian Journal of Research in Chemistry*. 2013;6(1):58-63.
35. Gumulapuram SH, Thota SR, Kumar VR, Nagabandi VK. Stability indicating RP-HPLC method development and validation for the simultaneous estimation of eprosartan mesylate and hydrochlorothiazide in bulk and tablet dosage form. *Int. J. Pharm. Pharm. Sci*. 2014;6(2):446-51.
36. Rozet E, Ceccato A, Hubert C, Ziemons E, Oprean R, Rudaz S, Boulanger B, Hubert P. Analysis of recent pharmaceutical regulatory documents on analytical method validation. *J Chromatogr A*. 2007;1158(1-2):111-25.
37. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. ICH Q2(R2): Validation of Analytical Procedures. Geneva: ICH; 2023
38. Sireesha D, Sravya E. Development and validation of RP-HPLC method for the estimation of sitagliptin phosphate in tablet dosage form. *International Journal of Applied Pharmaceutical Sciences and Research*. 2017;2(03):41-5.
39. Divya P, Aleti P, Venisetty RK. Development and validation of RP-HPLC method for the simultaneous estimation of Aliskiren and Amlodipine in tablet dosage form. *International Journal of Pharma and Biosciences*. 2013;3(4):241-46.
40. Thaidala Sriveni, Vanamala Naveen, Vemula Sai Rupa, Aeruva Renuka, Sunil Porika, M Akiful Haque, Vasudha Bakshi, Narender Boggula. Development and Validation of Dolutegravir in Bulk and Formulation: An Anti-Retroviral Drug Using UV-Spectroscopy. *International Journal of Pharmaceutical Quality Assurance*. 2021;12(1):57-60.
41. Kudikala S, Malladi SR, Thota S, Kumar VR. RP-HPLC method for the estimation gemcitabine in API and parenteral dosage form. *Journal of Scientific Research in Pharmacy*. 2014;3:16-8.
42. Gayathri S, Sireesha D, Haque MA, Harshini S, Bhakshi V, Reddy SK. Method development and validation of RP-HPLC method for simultaneous estimation of Olmesartan medoxomil and Hydrochlorothiazide in bulk and pharmaceutical dosage form. *International Journal of Pharma Research and Health Sciences*. 2014;2(6):457-62.
43. Kolagani S, Thota S, Neerati V. Development and validation of stability indicating RP-HPLC method for the estimation of neuroleptic drug of Zotepine in bulk and tablet dosage form. *Int J Pharm Sci*. 2014;6:456-9.
44. Pokala M, Rani PJ, Pranathi G, Haque MA, Sireesha D, Harshini S, Vasudha B. Development and validation of RP-HPLC method for the simultaneous estimation of amlodipine and metoprolol in bulk and pharmaceutical dosage form. *Indo Am. J. Pharm. Res*. 2015;5(10):3254-60.
45. Swapna B, Kiran G, Vasudha B, Kumar JR. Stability indicating RP-HPLC method for simultaneous estimation of betamethasone dipropionate and calcipotriene in bulk and pharmaceutical dosage form. *Biointerface Research in Applied Chemistry*. 2018;8(1):3089-94.
46. Godi NR, Dodda S, Vanga NR, Ummiti K. Identification and characterization of unknown oxidation degradation products of Rimegepant by HPLC and triple quadrupole

- mass spectrometry. *European Journal of Mass Spectrometry*. 2025;31(1-2):38-50.
47. Bairagi A, Kothrukar R, Chikhale H, Kosanam S, Borse L. AQbD-novel strategy for analytical methods. *Future Journal of Pharmaceutical Sciences*. 2024;10(1):138.
48. Khambhampati R, Dodda S, Jadi RK. Development and validation of stability indicating methods for the simultaneous estimation of antiviral drugs Darunavir and Ritonavir by RP-HPLC in bulk and dosage forms. *Appl Chem Eng*. 2024;7(1).
49. Müller F, Bange T. Identification of N-degrons and N-recognins using peptide pull-downs combined with quantitative mass spectrometry. In *Methods in Enzymology* 2023 Jan 1 (Vol. 686, pp. 67-97). Academic Press.
50. Pirok, Bob WJ, Dwight R. Stoll, and Peter J. Schoenmakers. Recent developments in two-dimensional liquid chromatography: fundamental improvements for practical applications. *Analytical Chemistry*. 2018; 91(1):240-63.